About This Research Desk

What LKN Peptides is

LKN Peptides is an independent editorial reference desk covering three compounds studied in and around the growth-hormone (GH) axis: CJC-1295, the CJC-1295/ipamorelin combination, and MOTS-c, the lead compound on this desk. The organizing idea is stated in the theme itself — this is where the GH axis meets metabolic research, and the three compounds sit at different points along that line. CJC-1295 works directly on the pituitary gland's GHRH receptor. The CJC-1295/ipamorelin combination adds a second pituitary receptor pathway to that same mechanism. MOTS-c abandons pituitary signaling altogether and works through a mitochondrial-to-cellular pathway that intersects with GH-axis metabolism without sharing its receptors.

This desk's defining habit is skepticism about evidence quality, applied evenly. A citation from a five-person pilot study is described as a five-person pilot study. A finding from mice is described as a finding from mice. A claim that rests only on mechanism, with no direct measurement behind it, is labeled as such. This is not equivalent to saying these compounds do not work — it is a refusal to round up thin evidence into a stronger claim than it supports.

How it is compiled

Three habits govern what appears on this site.

First, every research claim traces to a numbered citation on the references page — a peer-reviewed journal article, a preprint identified as such, or a named regulatory document — with a DOI or PubMed link wherever one exists.

Second, this desk states the species, sample size, and study design behind every finding, not just its headline result. A mouse study is identified as a mouse study in the body text, not folded silently into general language about 'research shows.' A single-cohort human study, like the 94-patient MOTS-c hemodialysis cohort, is identified as exactly that — one cohort, one population, not a general finding about healthy adults.

Third, where a compound or combination has simply not been tested — the CJC-1295/ipamorelin blend as sold, for instance, or any human dosing protocol for MOTS-c — this site says so directly, rather than inferring an answer from adjacent data and presenting it as settled.

What it is not

LKN Peptides is not a supplier, vendor, or clinic. It does not sell, source, or broker CJC-1295, ipamorelin, MOTS-c, or any other compound, and it has no referral or affiliate relationship with any research-chemical vendor or telehealth provider. It does not recommend a dose, schedule, or route of administration for anyone, and where a dose figure appears in this site's text, it is describing a specific published study, not offering guidance.

None of the three compounds covered here is approved for human use by the FDA or any other regulator. Readers with a health question should consult a licensed clinician; this desk exists to describe the published literature accurately, not to substitute for that consultation. Editorial correspondence — citation corrections, newly published studies, updated regulatory status — can be directed to the contact page.